Greehey CCRI News & Events

Archive

Filter results


 

Business Wire: Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.

September 20, 2022

Webinar to be hosted on Thursday, Sept. 22, 2022, at 12:00 p.m. ET, register here. Dr. Houghton will discuss challenges in drug development for pediatric cancers and preliminary results from Lantern’s drug candidates in preclinical pediatric cancer mod …


UT Health SA Newsroom: CPRIT awards $8 million for Greehey Children’s Cancer Research Institute core labs

September 15, 2022


Business Wire: Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights, Scientific Collaborations Updates (Houghton)

August 9, 2022

During Childhood Cancer Awareness Month in September, Lantern will host a KOL webinar featuring Dr. Peter Houghton, Ph.D., a leading expert in childhood cancers at the Greehey Children’s Cancer Institute at the University of Texas San Antonio Health Sc …


Molecular Cancer Theraputics: Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium (Houghton, Kurmasheva)

August 3, 2022

Pooja Hingorani Wendong Zhang; Zhongting Zhang; Zhaohui Xu; Wei-Lien Wang; Michael E. Roth Yifei Wang; Jonathan B. Gill Douglas J. Harrison; Beverly A. Teicher; Stephen W. Erickson Gregory Gatto; Edward A. Kolb Malcolm A. Smith Raushan T. Kurmasheva Pe …


Clinical Cancer Research: Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models (Houghton & Kurmasheva)

August 1, 2022

Fuyang Li; Kathryn M. Bondra; Samson Ghilu; Adam Studebaker; Qianqian Liu Joel E. Michalek Mari Kogiso; Xiao-Nan Li John A. Kalapurakal; C. David James; Sandeep Burma; Raushan T. Kurmasheva Peter J. Houghton Abstract Purpose: We investigated why three …


Molecular Cancer Therapeutics: Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma (Houghton, Kurmasheva)

June 1, 2022

Yifei Wang; Xiangjun Tian; Wendong Zhang; Zhongting Zhang; Rossana Lazcano; Pooja Hingorani; Michael E. Roth; Jonathan D. Gill; Douglas J. Harrison; Zhaohui Xu; Sylvester Jusu; Sankaranarayanan Kannan; Jing Wang; Alexander J. Lazar; Eric J. Earley; Ste …


SAVE-THE-DATE: San Antonio Pediatric Cancer Symposium (SAPCS)

May 10, 2022

The San Antonio Pediatric Cancer Symposium (SAPCS), hosted by the Greehey Children’s Cancer Research Institute at UT Health San Antonio and in conjunction with the Mays Cancer Center, will bring together some of the most respected childhood cancer rese …


Clinical Cancer Research: The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models (Kurmasheva & Houghton)

April 22, 2022

Nathan M Kendsersky # 1 2, Jarrett Lindsay # 1 2, E Anders Kolb 3, Malcolm A Smith 4, Beverly A Teicher 4, Stephen W Erickson 5, Eric J Earley 5, Yael P Mosse 1, Daniel Martinez 6, Jennifer Pogoriler 2 6, Kateryna Krytska 1, Khushbu Patel 1 7, David Gr …


Cancer Research: M6A RNA Methylation Regulates Histone Ubiquitination to Support Cancer Growth and Progression (Gupta, Zheng, Houghton, Chen, and Rao Labs)

March 21, 2022

Pooja Yadav; Panneerdoss Subbarayalu; Daisy Medina, Saif Nirzhor;  Santosh Timilsina; Subapriya Rajamanickam; Vijay K. Eedunuri; Yogesh Gupta Siyuan Zheng Nourhan Abdelfattah Yufei Huang Ratna Vadlamudi Robert Hromas; Paul Meltzer Peter Houghton; Yidon …


BioSpace: Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children’s Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio (Houghton)

February 16, 2022

      Published: Feb 15, 2022 Original Publication: BioSpace – Lantern Pharma’s A.I. and machine learning platform, RADR®, aided in the identification of additional pediatric cancers where Lantern’s portfolio of drug candidates can be le …


  • Page 1 out of 11
  • Next